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Natural Killer (NK) cells are potent cytotoxic cells belonging to the family of Innate
Lymphoid Cells (ILCs). Their most characterized effector functions are directed to the
control of aberrant cells in the body, including both transformed and virus-infected cells.
NK cell-mediated recognition of abnormal cells primarily occurs through receptor-ligand
interactions, involving an array of inhibitory and activating NK receptors and different
types of ligands expressed on target cells. While most of the receptors have become
known over many years, their respective ligands were only defined later and their
impressive complexity has only recently become evident. NKp44, a member of Natural
Cytotoxicity Receptors (NCRs), is an activating receptor playing a crucial role in most
functions exerted by activated NK cells and also by other NKp44+ immune cells.
The large and heterogeneous panel of NKp44 ligands (NKp44L) now includes surface
expressed glycoproteins and proteoglycans, nuclear proteins that can be exposed
outside the cell, and molecules that can be either released in the extracellular space
or carried in extracellular vesicles. Recent findings have extended our knowledge on
the nature of NKp44L to soluble plasma glycoproteins, such as secreted growth factors
or extracellular matrix (ECM)-derived glycoproteins. NKp44L are induced upon tumor
transformation or viral infection but may also be expressed in normal cells and tissues.
In addition, NKp44-NKp44L interactions are involved in the crosstalk between NK cells
and different innate and adaptive immune cell types. NKp44 expression in different ILCs
located in tissues further extends the potential role of NKp44-NKp44L interactions.
Keywords: natural kiiler cells, innate lymphoid cells (ILC), natural cytotoxicity receptors (NCR), NKp44, ligands,
tumor immunology, viral infections
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INTRODUCTION
NK cells are cytotoxic Innate Lymphoid Cells (ILCs) that
patrol the body and play a crucial role in the defense against
viruses and tumors by circulating in peripheral blood (PB)
and extravasating into tissues, in particular at the sites of
injury (1–8). In addition to recirculating NK cells, specific
NK cell subsets reside in different tissues and organs fulfilling
unique regulatory functions. Depending on the organ and
the local microenvironment, tissue-resident NK (trNK) cells
release proangiogenic factors, regulatory cytokines or specific
chemokines, and interact with different cell types. Recirculating
NK cells, besides killing target cells, can promote inflammation
by cytokine and chemokine release and interaction with
dendritic cells (DC), monocytes/macrophages, granulocytes, and
T cells (9–14).
NKp44, together with the other Natural Cytotoxicity
Receptors (NCRs), NKp46 and NKp30 (14–16) can play an
important role in most functions exerted by NK cells and also
by other immune cell types (17). Indeed, NKp44 expression
is wider than initially thought, and includes activated PB-
NK cells (15), interferon-producing intraepithelial ILC1 in
tonsils (18, 19), a subset of ILC3 in the decidua (20), and in
mucosal-associated lymphoid tissue (MALT) (21), a small subset
of decidual trNK cells (22), and plasmacytoid dendritic cells
(pDC) (23, 24). Typically, NKp44 is implicated in the killing
of virus-infected or tumor cells; however, the increasing panel
of NKp44+ cells and the identification of new NKp44-ligands
(NKp44L), possibly expressed in different tissues or released in
the circulation, supports an important role for this receptor in
tissue homeostasis and immune regulation (25–29).
NKp44 is a transmembrane glycoprotein characterized by a
single extracellular V-type Ig-like domain and a cytoplasmic
tail containing an Immunoreceptor Tyrosine-based Inhibitory
Motif (ITIM) and no known activating signaling motifs (16). The
crystal structure of the NKp44 Ig-V domain reveals the presence
of a prominent positively charged groove, likely involved in
recognition of anionic patterns shared by different ligands (30).
The transmembrane domain contains a charged amino acid (Lys)
that allows the association with the Immunoreceptor Tyrosine-
based Activating Motif (ITAM)-containing KARAP/DAP12
adaptor protein, a strong transducer of activating signals (16, 31–
33). Even if the NKp44 ITIM sequence was originally shown
to be non-functional (34), in certain contexts NKp44 can also
transduce inhibitory signals. Indeed, NKp44 expressed on pDC
inhibits IFN-α release induced upon TLR stimulation (23). More
recently, three NKp44 mRNA splice variants (NKp44-1,−2,−3)
have been demonstrated to display different signaling capabilities
based on the presence (NKp44-1) or absence (NKp44-2 and−3)
of the ITIM in their cytoplasmic tail. Local physiologic or
pathologic cytokine milieus could influence NKp44 splicing,
determining the relative expression levels of these variants and,
accordingly, affecting the functional features of NK cells in
different locations (see below) (35–37).
The local microenvironment can also determine the function
and role of NKp44 by orchestrating development, recruitment,
and modulation of specific regulatory, tissue-remodeling, or
cytotoxic NKp44+ cell subsets (either NK cells or ILCs). Thus,
for example, lungs contain a large majority of CD56dim NK
cells recirculating from blood; spleen and liver also include
CD56bright trNK cells; lymphoid tissues associated to epithelia
include NKp44+ ILCs; uterus comprises NKp44+ NK cells and
NKp44+ ILC3 with peculiar regulatory and tissue-remodeling
functions (2, 4, 5, 18, 19, 38, 39).
Pathologic conditions, and in particular tumors, can result
in altered patterns of NKp44+ cells. Tumor tissues can
produce specific cytokines and chemokines that can drive
recruitment of cytokine-producing or cytotoxic NK cell subsets
(i.e., CD56bright or CD56dim cells) (40, 41) and induce NKp44
expression. In addition, NKp44+ ILC3 have also been described
in lung tumors and have been found to be associated with
a better clinical outcome (39). On the other hand, in the
tumor microenvironment, hypoxic conditions (42), or soluble
mediators such as PGE2 (43–45) and TGF-β (46) can induce
NK cells to down-regulate expression and/or function of major
activating NK receptors including NKp44. Similar effects can
also be induced by tumor cells and tumor-associated fibroblasts
(45, 47).
Thus, depending on the type of available NKp44L, NKp44-
expressing cells, tissues, or environmental conditions, the role of
NKp44 greatly varies and extends to novel functional contexts,
beyond the classical NK-mediated target cell killing.
NKP44-NKP44L INTERACTIONS INVOLVED
IN RECOGNITION OF TUMOR AND
VIRUS-INFECTED CELLS
NKp44-Mediated Recognition of
Tumor Cells
Although NKp44L have been elusive for a long time since
the discovery of NKp44, experimental evidence suggested that
NKp44-NKp44L interactions occurring in the context of tumor
cell recognition could play an important role in potentiating
NK-mediated cytotoxicity against tumor cells (15, 16, 48, 49).
Figure 1A summarizes information on the presently known
NKp44-L and their role in the NK-tumor cell interaction.
The first evidence of an activating cellular NKp44L was
provided in 2005, when Vielliard et al. reported that an
NKp44L is induced on CD4+ T lymphocytes from HIV-1-
infected individuals (see below) (50). Later on, such NKp44L
was identified as a peculiar isoform of mixed-lineage leukemia
protein-5 (MLL5), termed 21spe-MLL5, encoded by a splice
variant lacking the last five exons of MLL5 and containing a
unique C-terminal exon, required for both localization at the
cell surface and interaction with NKp44 (51). MLL5 (or lysine
methyltransferase 2E), is primarily a nuclear protein with a wide
expression pattern in healthy tissues and plays a role in regulating
cell cycle progression and hematopoietic differentiation; on the
other hand, 21spe-MLL5 is mainly found in the cytoplasm
and at the cell surface, is barely expressed in healthy tissues
but is frequently detected at high levels in hematopoietic and
non-hematopoietic tumor cells. The mechanism allowing the
expression of this ligand on the surface of cancer cells is still to
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FIGURE 1 | NKp44-NKp44L interactions and their role in the recognition of tumor (A) or virus-infected cells (B) by human NK cells. (A) Shows cellular and
cell-released NKp44 ligands expressed by tumor cells. (B) Shows viral and viral-regulated NKp44 ligands. Viruses up-regulating/down-regulating NKp44L expression
on infected cells are indicated with up and down arrows. Green arrows indicate interactions resulting in NK cell activation, while red arrows indicate inhibition. Black
arrows refer to still undefined interactions. MLL5, mixed-lineage leukemia protein-5; PCNA, Proliferating Cell Nuclear Antigen; HSPG, heparan sulfate proteoglycans;
NID1, Nidogen-1; PDGF, Platelet-Derived Growth Factor; SDC4, syndecan-4.
be defined, but 21spe-MLL5 surface expression on tumor cells
triggers NKp44-mediated cytotoxicity (51).
Another cellular NKp44L is represented by Proliferating
Cell Nuclear Antigen (PCNA) (52), a ubiquitously expressed
nuclear protein involved in the regulation of DNA replication,
DNA repair, and cell cycle progression. Interestingly, it may
be overexpressed in cancer cells where it contributes to tumor
survival and enhanced malignancy (53). PCNA can be recruited
to the plasma membrane of tumor cells, probably through the
formation of a PCNA/HLA-I complex (54) or shuttling via
exosomes (52). NKp44 engagement by PCNA results in the
inhibition of NK-mediated cytotoxicity and IFN-γ secretion by
NK cells; this inhibitory effect is mediated by the ITIM in NKp44
cytoplasmic tail and is observed only following an interaction
with the ITIM-containing isoform NKp44-1, whose expression
has been associated with poor survival in AML patients (36). In
view of these findings, PCNA has been proposed as an immune
evasion mechanism, enhancing tumor cell survival by promoting
a paradoxical NKp44-mediated inhibition of tumor cell killing
by NK cells. Recently, the NKp44 binding site for PCNA was
identified and an NKp44-derived peptide has been shown to
target intracellular PCNA, resulting in the apoptosis of cancer cell
lines in vitro and tumor growth arrest in vivo (55).
Cell surface-associated heparan sulfate (HS) proteoglycans
(HSPGs) represent a peculiar category of NCR ligands (56). The
three NCRs display a distinct pattern of HS/heparin recognition,
based on the heterogeneity and structural complexity of
these macromolecules (57). NKp44 recognizes highly sulfated
HS/heparin-type structures by binding to negatively charged
stretches of HS. Mutations of basic residues in the positively
charged NKp44 groove resulted in a decreased binding to
HS/heparin. In the context of tumor cell recognition, NKp44may
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bind to HS expressed on different cancer cell lines. Moreover, HS
was able to enhance NKp44-induced IFN-γ secretion, while the
role of HS in the induction of NK-mediated cytotoxicity is less
clear (58). Althoughmembrane-associated HSPGs are present on
all cells, their expression is heterogeneous in different tissues and
can be altered in tumor cells (59). Modified levels of HS in cancer
cells may result in altered recognition, in their association with
other ligands, or in their structural alterations by tumor-induced
modifying enzymes. In this context, HS moieties of HSPGs may
be considered as self “modified” ligands for NCRs and may serve
as co-ligands, cooperating with other ligands to influence NK
cell functions.
NKp44 has also been shown to interact in cis with syndecan-4
(SDC4), one of the HSPGs expressed on the surface of NK cells,
thereby constitutively dampening NKp44-mediated activation by
preventing the receptor binding to other ligands expressed on
target cells (60).
More recently, the search for glycolipid
ligands by microarray screening led to the
identification of Globo-A (GalNAcα1,3(Fucα1,2)
Galβ1,3GalNAcβ1,3Galα1,4Galβ1,4Galβ1-Cer) as NKp44L
(61). This glycolipid, which was originally isolated from human
kidney, displays a globo-series structure and includes a terminal
part similar to that of blood group A antigen (62). At present, its
functional relevance in the regulation of NK cell function has not
been demonstrated yet.
NKp44-Mediated Recognition of
Virus-Infected Cells
Concerning the role of NKp44 in the context of virus recognition,
roughly three types of viral interactions have been described: viral
NKp44L, virus-induced up-regulation of cellular NKp44L, and
virus-mediated inhibition of NKp44 recognition (Figure 1B).
In 2001, Mandelboim et al. reported that the hemagglutinin
(HA) of the orthomyxovirus H1N1 influenza virus and
the hemagglutinin-neuraminidase (HN) of the paramyxovirus
Sendai virus, both expressed on the surface of infected cells, are
recognized by NKp46, and thereby trigger the lysis of infected
cells by NK cells (63). Shortly thereafter, these viral proteins
were also found to serve as NKp44L, but not NKp30L, and the
interaction with NKp44 could contribute to the killing activity
of certain NK cell clones (64). NKp44 not only recognizes the
influenza virus HA of H1 strains but also of H5 strains (65). In
addition, HN of other paramyxoviruses, avian Newcastle disease
virus and human parainfluenza virus 3 (HPIV3), also appear to
serve as NKp44L and trigger NK cell activity (66, 67).
The recognition of both HA and HN depends on sialylation of
NKp44, similar to that reported for NKp46 (63–65). Remarkably,
the E envelope glycoproteins of two flaviviruses, West Nile and
Dengue viruses, also bind to NKp44 thereby increasing NK cell
activity, but in a sialylation-independent manner (68).
As mentioned above, in 2005, Vieillard et al. reported that
a fraction of CD4+ T cells from HIV-infected patients, but
not from healthy subjects, showed an increased expression of
NKp44L (50). The percentage of NKp44L+ CD4+ T cells was
inversely correlated with the CD4+ T cell count and correlated
with the viral load, suggesting that NKp44L expression may be
implicated in T cell depletion and disease course. In addition,
the HIV gp41 envelope protein (and its precursor gp160) was
found to trigger NKp44L expression and NK-mediated lysis. In
particular, a highly conserved peptide in gp41 (NH2-SWSNKS-
COOH or 3S) triggers NKp44L expression (50). Another study
suggested that a role for virus-induced NKp44L expression in
CD4+ T cell depletion during HIV infection may be virus strain-
dependent (69).
Members of two large DNA virus families, the poxviruses and
the herpesviruses, also up-regulate the expression of NKp44L
early after infection of host cells. The immediate early ICP0
protein of herpes simplex virus 1 and an unidentified early
protein of the poxvirus vaccinia virus up-regulate expression
of NKp30L, NKp44L, and NKp46L, thereby triggering NCR-
mediated lysis of infected human fibroblast cells (70, 71).
Viral interference with the NKp44-mediated killing of infected
cells typically consists in the down-regulation of cellular or
viral NKp44L from the cell surface. Remarkably, the same HIV
gp41 S3 peptide that triggers NKp44L expression in CD4+ T
cells, suppresses NKp44L expression in astrocytes. This led the
authors to hypothesize that HIV may use this strategy to protect
astrocytes fromNK cell-mediated killing during HIV infection of
the CNS (72). How the same viral peptide exerts such opposing
effects on NKp44L expression and NK cell-mediated cytotoxicity
in two different cell types is currently unclear.
The viral ORF54-encoded protein of Kaposi’s sarcoma-
associated herpesvirus, but not that of other human
herpesviruses, suppresses the expression of NKp44L during
lytic infection. Although this viral protein is a dUTPase,
its enzymatic activity is neither necessary nor sufficient to
down-regulate NKp44L (73).
Finally, although the influenza virus HA binds NKp44 and
NKp46, thereby contributing to NK-mediated lysis of infected
cells, the virus can suppress this effect via expression of its NA
protein (74, 75). NA displays sialidase activity which may remove
the sialic acids from NKp44 and NKp46, thereby interfering
with their binding to HA (74, 75). Although the HA-NA-NKp44
interplay may appear paradoxical at first sight, perhaps this
should be looked upon from an evolutionary point of view. The
highly conserved function of influenza HA is to interact with
sialic acids on the cell surface as an essential initial step to enter
host cells. It has been hypothesized that NK cells utilize this
general HA sialic acid-binding property to recognize the infected
cell via NKp46 and NKp44 (75). The NA protein may then
serve as a viral countermeasure against these and other unwanted
side-effects of the essential sialic acid-binding activity of HA.
REGULATORY AND HOMEOSTATIC
FUNCTIONS OF
NKP44-NKP44L INTERACTIONS
NKp44 is also expressed on helper ILCs, which typically reside
at the epithelial/mucosal surfaces, becoming involved in tissue
remodeling, inflammation, and maintenance of barrier integrity
(76). Notably, NKp44 expression allows to discriminate two
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ILC3 subsets characterized by unique cytokine patterns: NKp44+
ILC3 are able to produce IL-22 (21) and are dependent on the
Aryl Hydrocarbon Receptor, whereas human LTi and NKp44neg
ILC3 produce IL-17A (77). Remarkably, in NKp44+ ILC3, IL-
22 expression is preferentially induced by cytokine stimulation,
whereas NKp44 triggering selectively activates a coordinated
pro-inflammatory program via TNF-α (78). In this context,
NKp44 has been suggested to play a potential role in the
pathogenesis of immune-mediated diseases, including psoriasis.
Indeed, more than 50% of circulating NKp44+ ILC3 in the blood
of psoriasis patients express cutaneous lymphocyte-associated
antigen, suggesting their role in skin homing.Moreover, NKp44+
ILC3 frequency in non-lesional psoriatic skin is significantly
increased when compared to that in normal skin (79).
NKp44+ ILC3 are also present in secondary lymphoid organs
(SLO). Differently from ILC3 in inflamed tonsils, ILC3 in
non-inflamed lymph nodes and spleen, irrespective of NKp44
expression, lack the transcription of cytokines typicallymediating
ILC3 function. However, both NKp44neg and NKp44+ resting
ILC3 can produce IL-22 in response to inflammatory stimuli.
According to these data, SLO-residing ILC3may represent a pool
of resting cells that can be rapidly activated by inflammatory
signals present in the local microenvironment (80).
NKp44+ ILC3 can also infiltrate tumor tissues. In particular,
in non-small cell lung cancer, NKp44 can interact with
tumor cells and synergize with IL-1β and IL-23 for IL-22
production (39). In addition, NKp44-mediated recognition
of tumor associated fibroblasts can lead to the release
of high amounts of TNF-α, thus influencing the vascular
permeability and inducing pro-inflammatory responses in the
tumor microenvironment (39).
In the uterus, the NKp44+ pool is composed of ILC3,
LTi-like cells, IFN-γ-producing ILC1-like cells, and NK cells
(20, 22). These cell populations are variably involved in tissue
remodeling related to decidua development and vascularization
during pregnancy, the induction of maternal-fetal tolerance, and
the control of viral infections (i.e., CMV) (81). For some of
these functions the role of NKp44 has been suggested by its
ability to induce IP10, IL-8, and VEGF release (82). It has also
been recently shown that the decidual cytokine milieu can favor
the expression of the ITIM-bearing NKp44-1 inhibitory isoform
(37), which indeed can induce cytokine release but inhibits
cytotoxicity. In this context, the overexpression of the NKp44-L
PCNA in decidual throphoblasts in the first trimester of gestation
suggests that inhibitory signaling of NKp44 might contribute
to the maintenance of immune tolerance of maternal NK cells
during pregnancy (83).
As mentioned in the Introduction, the functional role of
NKp44 also depends on the nature and body distribution of its
ligands. Very recently, the discovery of Platelet-Derived Growth
Factor (PDGF)-DD as a novel NKp44L represented a major
breakthrough, since for the first time NKp44 was demonstrated
to recognize a soluble molecule (28, 84). PDGF-DD belongs to
the PDGF family and represents the active processed form of
PDGF-D (85, 86). Noteworthy, PDGF-DD-NKp44 interaction
does not trigger NK cell-mediated cytotoxicity, rather, it induces
potent release of TNF-α and IFN-γ by IL-2-activated NK cells.
Transcriptomic analysis clearly indicated that stimulation of
activated NK cells by PDGF-DD induced genes encoding pro-
inflammatory cytokines and chemokines, cell surface activation
markers, and transcription factors involved in ITAM signaling,
cellular activation, and proliferation. Notably, the induction of an
NKp44-dependent pro-inflammatory program upon PDGF-DD-
NKp44 interaction has been demonstrated not only in activated
NK cells but also in other NKp44+ ILCs, namely ILC3 and
intraepithelial ILC1. In particular, PDGF-DD induced IFN-γ and
TNF-α production in ILC1, while it stimulated TNF-α but not
IL-22 secretion in ILC3 (28).
PDGF-DD is involved in embryonic development, placenta
formation, angiogenesis, and wound healing, and has been
implicated in various pathological conditions, including vascular
diseases, mesangioproliferative glomerulonephritis, and fibrosis
(85, 87). Thus, PDGF-DD interaction with NKp44+ cells
present in various tissues (including decidua) may play diverse
biological roles. Nevertheless, PDGF-DD can be secreted by
different tumors and promotes cellular proliferation, stromal cell
recruitment, angiogenesis, epithelial-mesenchymal transition,
and metastasis through autocrine and paracrine PDGFRβ
signaling (88, 89). In this context, PDGF-DD, as NKp44L, can
also induce NK-, ILC1- and ILC3-mediated release of cytokines
with anti-tumor activity. Indeed, supernatants of PDGF-DD-
activated NK cells inhibit tumor cell growth in vitro, while in
vivo experiments indicated that the introduction of the NCR2
transgene limited the spread of PDGF-DD-expressing tumor cells
in mice (28).
The example of PDGF-DD as an extracellular ligand is not
unique among NCRs, since NKp46 can also bind to a soluble
molecule, namely the plasma glycoprotein Complement Factor
P (CFP or properdin) (90). Both CFP and PDGF-DD activate NK
cell functions. However, soluble ligands of activating receptors
generally represent mechanisms to modulate NK cell functions
(91–97). In this context, another peculiar NKp44L was recently
described (29). Nidogen-1 (NID1) glycoprotein is an essential
component of ECM and basement membrane (BM) (98, 99)
able to interact with NKp44. When released as soluble molecule,
NID1 modulates NK cell function by reducing NKp44-induced
IFN-γ release or cytotoxicity. Notably, it also regulates IFN-γ
production induced by PDGF-DD followingNKp44 engagement.
Thus, the release of NID1 in extracellular fluids may act as
regulatory mechanism for NKp44+ NK cells in the blood stream
or in tissues. Interestingly, NID1 release has been observed in
different cancer types (100–102), andmay represent a suppressive
mechanism exploited by tumors to avoid NK-mediated attack.
Actually, the functional outcome of the NKp44-NID1 interaction
may be rather complex, as NID1 can associate with other ECM
components, including laminin, collagen type IV, and perlecan
(98, 99), or be modified by extracellular proteases secreted in the
tumor microenvironment (103, 104). In addition, NID1 can also
be exposed at the cell surface of different NID1-releasing tumor
cell lines (29).
As shown by the examples of PDGF-DD and NID1, NKp44L
can be expressed not only on neoplastic or virus-infected cells,
but also on normal cells. Thus, NKp44L expression was observed
on the surface of articular chondrocytes (105), although the
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TABLE 1 | Expression of NKp44 ligands in human tissues.
Ligand (inhib/act NKp44)* Tissues
PCNAa,b
(inhibition through ITIM)
Nervous system: cerebral and prefrontal cortex, spinal cord, cerebellum
Endocrine tissues: adrenal, thyroid, parathyroid, and salivary glands, pancreas
BMe and immune system: B, T, and NK cells, monocytes, BM stromal cells, LNe, tonsil, spleen, appendix
Muscle tissues: heart, smooth and skeletal muscle
Respiratory system: lung, nasopharynx, bronchus
Skeletal system: bone
Digestive system: colon and ileum epithelial cells, colon, esophagus, gallbladder, gut, cardia, liver, oral epithelium, stomach, rectum,
duodenum, small intestine
Urinary system: kidney, bladder
Male tissues: testis, seminal vesicle, prostate gland, epididymis
Female tissues: breast, amniocytes, fallopian tube, myometrium, ovary, placenta, uterus, uterine cervix, vagina, endometrium
Adipose and soft tissues: adipocytes
Integumentary system: hair follicle, skin
21spe-MLL5c
(activation)
BM and immune system: CD4+ T cells from HIV-infected patients
Skeletal system: articular chondrocytes
Syndecan-4a,b
(inhibition through receptor
masking)
Nervous system: cerebral and prefrontal cortex, spinal cord, cerebellum, hippocampus, caudate
Endocrine tissues: adrenal, thyroid, parathyroid, and salivary glands, pancreas
BM and immune system: platelets, LN, tonsil, spleen, appendix
Muscle tissues: heart, smooth and skeletal muscle
Respiratory system: lung, nasopharynx, bronchus
Skeletal system: bone, chondrocytes
Digestive system: colon, gallbladder, liver, oral epithelium, rectum, small intestine, duodenum, stomach, esophagus
Urinary system: kidney, bladder
Male tissues: testis, seminal vesicle, prostate gland, epididymis
Female tissues: breast, amniocytes, fallopian tube, myometrium, ovary, placenta, uterine cervix, vagina, endometrium
Adipose and soft tissues: adipocytes, fibroblasts
Integumentary system: skin
PDGF-DDb,d
(activation)
Nervous system: cerebral cortex
Endocrine tissues: adrenal and thyroid gland
BM and immune system: LN, tonsil, spleen, appendix
Muscle tissues: heart, smooth muscle
Respiratory system: lung
Digestive system: colon, oral epithelium
Male tissues: seminal vesicle
Female tissues: breast, ovary
Integumentary system: skin
NID1a,b
(inhibition through receptor
masking)
Nervous system: arachnoid cyst, cerebral cortex, prefrontal cortex, spinal cord
Endocrine tissues: adrenal, thyroid, and salivary glands, pancreas
BM and immune system: platelets, mesenchymal stem cells, NK cells, LN, tonsil, spleen
Muscle tissues: colon muscle, heart
Respiratory system: lung, nasopharynx
Digestive system: colon, esophagus, gallbladder, gut, cardia, liver, oral epithelium, stomach, rectum;
Urinary system: kidney, bladder
Male tissues: testis, seminal vesicle, prostate gland, epididymis
Female tissues: breast, amniocyte, myometrium, ovary, placenta, uterus, uterine cervix
Adipose and soft tissues: adipocytes
Integumentary system: skin
*NKp44-NKp44L interactions can result in a different outcome depending on the ligand: activation or inhibition of NK cell functions.
aData obtained from ProteomicsDB.
bdata obtained from The Human Protein Atlas.
cdata obtained from refs (50, 51, 105).
ddata obtained from ref (107).
eBM, bone marrow; LN, lymphnodes.
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nature of this ligand is not well-defined. Since NK cells can kill
human chondrocytes, it has been suggested that the NKp44-
NKp44L interaction may play a role in cartilage destruction
occurring in chronic inflammatory joint disorders. Interestingly,
human NK cells were previously shown to kill porcine
chondrocytes mainly through NKp44-NKp44L interaction (106).
More recently, it has been demonstrated that human
astrocytes express an NKp44L whose interaction with NKp44
contributes to NK-mediated cytotoxicity against astrocytes and
to IFN-γ production (72).
CONCLUDING REMARKS
The finding that NKp44 is expressed by different immune cell
types and tissues (Table 1) and can recognize multiple ligands
(soluble or associated to the cell surface or ECM) strongly
suggests that this receptor is used to fulfill various functions,
adapted to different body compartments or even to temporary
micro-environmental changes.
The expanding knowledge on the multifaceted role of
NK cell subsets and ILCs, residing in the different tissues,
suggests that NKp44-NKp44L interactions may be involved
in the activation/regulation of several biological/immunological
processes. A deeper understanding of these issues will be
beneficial for the design of NK-based immunotherapeutic
approaches in different pathologic conditions, including but not
limited to tumors and infections.
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